Institute for Protein Innovation

What Institute for Protein Innovation does

The Institute for Protein Innovation (IPI) is an independent nonprofit research institute founded in 2017 and headquartered in Boston, MA, that discovers, develops, and distributes synthetic recombinant antibodies and protein reagents to the global biomedical research community. Its core technology platform uses yeast display for synthetic antibody library screening, combined with in vitro protein engineering, automated high-throughput protein production, and the open-source pTipi2 expression vector. IPI systematically targets entire protein families — including integrins, neurexins, neuroligins, axon guidance molecules, and common epitope tags — rather than individual targets, with particular emphasis on highly conserved neuronal proteins that traditional hybridoma methods struggle to address.

IPI distributes its antibody collections through a strategic partnership with Addgene, a global nonprofit biorepository shipping plasmids and reagents to 108 countries, and provides full antibody sequence disclosure under an open-science model. The organization supplements its reagent catalog with the Community Access Antibody Program (CAAP) for early-stage beta-testing, a five-day Yeast Display Technology for Antibody Discovery course, and the annual IPI Surfacing symposium on cell surface receptor biology. Its revenue model is philanthropy- and grant-funded rather than product-sales-based, anchored by a $210 million gift from co-founder Timothy Springer and his family announced in June 2023, with additional funding from the Chan Zuckerberg Initiative.

The primary customer segments are academic researchers and principal investigators in neuroscience, developmental biology, and cell biology, with a secondary segment of biotech and pharma companies seeking antibody discovery tools. As of May 2026, IPI has extended into therapeutic discovery enablement through a partnership with Alloy Therapeutics to develop synthetic humanized VHH/nanobody libraries. The organization is led by President and CEO Ken Fasman (joined November 2022), with co-founders Timothy Springer and Andrew Kruse serving on the board alongside Stephen Quake (joined early 2026), and a broader team of 11–50 staff.

Name

Institute for Protein Innovation

Legal name

Institute for Protein Innovation

Website

https://proteininnovation.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

IPI is a Boston-based nonprofit research institute founded in 2017 that discovers and distributes synthetic recombinant antibodies and protein reagents via yeast display technology and an open-science model, serving academic and biotech researchers in neuroscience and cell biology.

Ownership category

akta.pro rank

Product category

Research Antibodies and Protein Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

IP Due Diligence & Freedom-to-Operate (FTO) Analysis (BPAHAMAG)

akta.pro secondary industry

IP Litigation & Dispute Resolution (BPAHAMAE)

Keywords

• Recombinant antibodies
• Protein reagents
• Antibody discovery
• Yeast display technology
• Neuroscience research tools

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Nonprofit Research Institute Model: IPI operates as a nonprofit research institute funded primarily through philanthropy and grants. The organization was significantly enabled by a $210 million gift from co-founder Timothy Springer and the Springer family. Revenue is not generated through product sales; instead, antibodies and reagents are distributed at low cost or no cost to researchers through the Addgene repository under an open science model.
2. Grant Funding: IPI receives grant funding from organizations such as the Chan Zuckerberg Initiative to support specific research programs, including the development of next-generation protein tools for neuroscience research. These grants fund both the creation and open distribution of research tools.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

IPI is a nonprofit research institute that designs, produces, and distributes synthetic recombinant antibodies and protein reagents to the biomedical research community. It uses yeast display technology and high-throughput automation to discover antibodies targeting entire protein families, particularly challenging neuronal and cell surface proteins. All antibodies, plasmids, and sequences are distributed under an open science model through the Addgene biorepository to academic researchers worldwide.

Product overview

Institute for Protein Innovation (IPI) is a nonprofit research institute that provides synthetic recombinant antibodies and protein reagents to the biomedical research community. The core offering consists of multiple antibody collections targeting protein families in neuroscience and cell biology, including the Axon Guidance Antibody Collection, Synaptic Cleft Antibody Collection (featuring neurexin and neuroligin antibodies), Integrin Antibody Collection, and Epitope Tag Antibody Collection. IPI also offers the Control Antibody Collection and the Community Access Antibody Program (CAAP) for early-stage antibody testing. The platform is built on yeast display technology for antibody discovery, with distribution through Addgene. Supporting offerings include the pTipi2 open-source expression vector and the annual Yeast Display Technology for Antibody Discovery course. All products are delivered via an open science model with full sequence disclosure.

Differentiator

Problem solved

Functional benefit

Products and services

• Axon Guidance Antibody Collection Antibody collection targeting axon guidance molecules including ROBO, DCC, Slit, semaphorin, netrin, and related proteins involved in neuronal development and wiring. Distributed globally through Addgene to academic neuroscience researchers.
• Synaptic Cleft Antibody Collection Antibody collection targeting proteins in the synaptic cleft, including neurexins, neuroligins, and other synaptic adhesion molecules that mediate neuronal signal transmission. Distributed to neuroscience researchers globally.
• Integrin Antibody Collection Antibody collection targeting the integrin receptor family, transmembrane proteins that connect cells to the extracellular matrix and mediate cell adhesion and signaling. Distributed globally through Addgene.
• Epitope Tag Antibody Collection Antibody collection targeting common epitope tags (V5, c-Myc, HA, DYKDDDDK, Rho, His, Biotin, EE, GCN4, MBP, Strep) for protein detection, purification, and localization studies. Includes recombinant antibodies and encoding plasmids distributed through Addgene.
• Control Antibody Collection Reference control antibodies for experimental validation and quality control in research applications, distributed through Addgene.
• pTipi2 Expression Vector Open-source expression vector for mammalian protein production, developed by IPI and distributed through Addgene. Produces high yields for epitope tag antibodies and antibodies produced on the IPI platform, serving as a feasible alternative to commercial vectors with fewer usage restrictions.

Quantifiable outcome

• Over 100,000 plasmids distributed globally through Addgene infrastructure, reaching 108 countries
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Alloy TherapeuticscoreStrategic or Co-development Partner · 5 May 2026A strategic collaboration announced May 5, 2026, to create synthetic, humanized VHH (nanobody) libraries for next-generation antibody discovery. The partnership combines Alloy's integrated drug discovery platform ecosystem with IPI's in vitro protein engineering capabilities and expertise in synthetic antibody discovery. Libraries developed using yeast display technology are designed to improve stability, reduce immunogenicity, and enhance developability for bispecific and multispecific therapeutics. Both organizations are committed to making these advanced discovery tools broadly accessible to biotech and pharma researchers, particularly for complex biological targets in neuroscience.
• Stanford UniversityminorStrategic or Co-development Partner · 2 March 2026Stephen Quake, Lee Otterson Professor of Bioengineering and Applied Physics at Stanford University, joined IPI's Board of Directors in early 2026. Quake brings extensive experience in founding and leading large-scale scientific initiatives, including the Chan Zuckerberg Biohub Network. His board participation represents a strategic advisory relationship between IPI and Stanford.
• AddgenecoreChannel Partner/ Reseller/ Distributor · 8 June 2023A strategic partnership announced June 8, 2023, joining two nonprofits with aligned missions to accelerate biomedical research through the discovery, development, and distribution of recombinant antibodies and other protein and DNA reagents. Addgene distributes IPI's antibody collection alongside full amino acid sequences and expression plasmids, enabling researchers to produce antibodies in their own labs. Addgene handles global logistics, quality control, and customer support, while IPI provides scientific expertise and validation data.
• Various Academic CollaboratorsminorStrategic or Co-development PartnerIPI collaborates with academic researchers at multiple institutions including Weill Cornell Medicine, UC San Diego, Brown University, University of Colorado, Wyss Institute at Harvard, Allen Institute for Neural Dynamics, University of Manitoba, and Tulane University. These collaborations involve antibody validation, beta-testing programs, and joint research projects focused on neuroscience and synaptic biology.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Addgene: Nonprofit global biorepository that distributes IPI's antibodies and plasmids. Addgene shares the open-science mission and nonprofit distribution model, serving the same academic researcher customer base across 100+ countries.
• Alloy Therapeutics: Antibody discovery platform company and IPI's VHH/nanobody library partner. Alloy operates a shared research ecosystem across antibodies and emerging therapeutic modalities, directly overlapping IPI's antibody discovery capabilities for therapeutic development.
• Atlas Antibodies: Antibody company focused on highly characterized research-grade antibodies including the Human Protein Atlas portfolio. Comparable to IPI in its emphasis on specificity, reproducibility, and coverage of under-served protein targets.

Broad incumbents

• Cell Signaling Technology: One of the largest commercial providers of primary antibodies and protein research reagents. Competes with IPI for academic research budgets but operates a for-profit model with proprietary reagent catalogs.
• Abcam: Global commercial antibody reagent company now part of Danaher. Serves the same academic and biotech research customers IPI targets, with a much broader catalog but proprietary sequences and reproducibility concerns IPI explicitly differentiates against.
• GenScript: Biotech providing antibody discovery, production, and protein engineering services. Overlaps IPI's custom antibody and recombinant protein capabilities for both academic and therapeutic customers.
• BioLegend: Major antibody and reagent manufacturer (now part of PerkinElmer/Revvity). Targets flow cytometry, neuroscience, and cell biology research with deep catalog breadth comparable to IPI's neuroscience focus.
• Allen Institute: Large nonprofit neuroscience research organization. Shares IPI's open-science ethos and neuroscience protein-tooling priorities; Karel Svoboda at the Allen Institute is a published IPI antibody user.

Others

• Chan Zuckerberg Biohub Network: Nonprofit research initiative funded by the Chan Zuckerberg Initiative with an open-science model analogous to IPI's. Stephen Quake, a recent IPI board addition, was the founding co-president of CZ Biohub.
• Howard Hughes Medical Institute: Major nonprofit biomedical research organization with a shared model of philanthropy-funded, open scientific output. Stephen Quake served as an HHMI Investigator before joining IPI's board.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCAbaWbusrqptucnfHObWe_A
• LinkedInlinkedin.com/company/ipiproteins
• Instagraminstagram.com/ipiproteins

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute for Protein Innovation